HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 01-04-2010, 07:26 PM   #1
Joe
Webmaster
 
Joe's Avatar
 
Join Date: Feb 2005
Location: Home of the "Flying Tomato" Carlsbad, CA
Posts: 2,036
Images: 5
Everolimus Helps Overcome Herceptin Resistance

I posted some clinical trial information about this rug today: Trial Information

Everolimus May Help Thwart Trastuzumab Resistance In Breast Cancer Patients
08 Oct 2009

BERLIN - New data identify a possible role for everolimus in reversing or delaying the onset of trastuzumab resistance in breast cancer patients.

The findings are from two trials presented at the joint 15th European Cancer Organization (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress.

Everolimus is an oral mTOR inhibitor that is approved for the treatment of patients with advanced renal cell carcinoma whose disease has progressed on or after treatment with vascular endothelial growth factor-targeted therapy.

The drug has also been shown to reverse trastuzumab resistance caused by PTN loss in preclinical studies and additionally has shown anti-tumor activity as a single agent in patients with metastatic breast cancer.

Dr. Sara Hurvitz, with the UCLA School of Medicine, and colleagues conducted a study to establish the feasible dose schedule for daily and weekly administration of everolimus combined with weekly trastuzumab and paclitaxel in patients with HER-2 overexpressing metastatic breast cancer whose disease had progressed during or after trastuzumab therapy.

Results in 33 patients showed that the combination was well tolerated and that the recommended starting dose for the phase II study is 10 mg daily.

Combination therapy involving everolimus, paclitaxel, and trastuzumab demonstrated "encouraging" efficacy in this heavily treated population of patients refractory to trastuzumab and taxanes. In particular, everolimus demonstrated activity in all patients who were evaluable for efficacy and assigned to the 5 mg everolimus treatment group.

The disease control rate was 85% (28 of 33 evaluable patients).

Biomarker results were similar to those observed during everolimus monotherapy in patients with metastatic renal cell cancer and suggest that the activity of everolimus is mediated in part through inhibition of VEGF-A-driven angiogenesis, Dr. Hurvitz said.

In a second study, similar results were obtained with the combination of everolimus (5 mg daily or 20 or 30 mg weekly) with vinorelbine and trastuzumab.

Dr. Fatima Cardoso, with the Jules Bordet Institute in Brussels, reported that the combination was feasible and tolerable in a similar heavily pretreated group of breast cancer patients and also showed promising clinical activity with a relevant long-term disease control. The disease control rate was 80% (37 of 46 evaluable patients).

In the study, there was no limit to the number of prior antineoplastic treatments.

Overall, 30 patients were assigned to a 5 mg daily dose of everolimus, and 20 patients received a 20 or 30 mg weekly dose.

Dr. Cardoso said that the addition of everolimus can bolster the therapeutic activity of vinorelbine and trastuzumab and reverse or postpone the onset of trastuzumab resistance.
__________________
A Proud webmaster to the internet's most informed, educated, COMPASSIONATE and caring group of breast cancer survivors.

Illegitimi non carborundum


My Album
Joe is offline   Reply With Quote
Old 01-05-2010, 04:42 AM   #2
Ellie F
Senior Member
 
Join Date: Feb 2009
Posts: 1,526
Re: Everolimus Helps Overcome Herceptin Resistance

Thanks Joe
This is really encouraging. Let's hope things move along quickly.
Ellie
Ellie F is offline   Reply With Quote
Old 06-12-2010, 03:00 PM   #3
Rob
Member
 
Join Date: Jun 2009
Posts: 20
Re: Everolimus Helps Overcome Herceptin Resistance

Joe, thanks for Enverolimus info. Daughter-in-law developed Herceptin resistant tumor, and now after a year plus on Tykerb/Xyloda, the tumor is spreading in the spine. She is Canadian though, and I hear Canada doesn't resupport Herceptin therapy.
Rob is offline   Reply With Quote
Old 06-28-2011, 07:13 PM   #4
Naudia
Member
 
Join Date: Jun 2011
Posts: 6
Re: Everolimus Helps Overcome Herceptin Resistance

It is great to hear that there is some hope on the horizon for cancer patients. Hopefully things will move along quickly to make this treatment readily available to those who need it. I am wondering if anyone has had atlas america insurance? If so, what do you think of them? Would you recommend them to other cancer patients? Thank you.
Naudia is offline   Reply With Quote
Old 09-06-2011, 02:12 PM   #5
kykeon22
Senior Member
 
Join Date: Aug 2011
Posts: 51
Re: Everolimus Helps Overcome Herceptin Resistance

Thanks for sharing, very promising.
__________________
Son of Ha

She has been dignosed in February 2008 BC state IV, left breast multiple nodes size 5 cm, mets lungs and liver. Er+ Pr+ Her neu +++.
3/2008 - 10/2010 Herceptin + Aramidex NED
10/2010 recurrence lung met, pleural effusion, toracentesis
11/2010- Tyverb + Navalbine NED
08/2011 CA-15-3 = 90 scan
08/2011 Scan revealed reccurrence lung met, tiny metastasis on the pleura and pleural effusion.
4 pills tyverb, mytoxantrone once ever three weeks, and Aromasin.
Tykerb and taxol, sever allergic reaction
Tykerb taxotere
Herceptin, perjeta, gemcitabina
C- diff, bad diarrea
Halevan and tamoxifen, tm down from 1200 to 130

kykeon22 is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 01:45 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter